|
|
|
Issue Open Date
|
29-Nov-24
|
|
|
|
Issue Closing Date
|
03-Dec-24
|
|
|
|
Application Money
|
100
|
|
|
|
Allotment Money
|
|
|
|
|
|
|
|
Price Band
|
420
-
441
|
|
|
|
Minimium Application No.
|
34
|
|
|
|
Issue Size (Shares)
|
13432533
|
|
|
|
Market Lot
|
1
|
|
|
|
|
|
Objective
|
|
|
|
|
|
|
|
|
Category
|
No. of Shares
|
No. of Shares
|
Subscription Ratio
|
|
|
Offered / Reserved |
Bid For |
|
|
Non-Institutional Investors
|
2878400
|
4045218
|
1.40537034463591
|
|
Qualified Institutional Buyers
|
3837867
|
6667332
|
1.73724936273195
|
|
Retail Individual Investors
|
6716266
|
6352730
|
0.945872304640704
|
|
|
|
|
Business Description
We are the largest full-service and integrated diagnostic chain headquartered in east India, by operating income as of Fiscal 2023. (Source: CRISIL Report). We also reported the highest compounded annual growth rate (“CAGR”) of 20.87% in terms of non-COVID revenues between Fiscals 2022 and 2024 among peers Agilus Diagnostics Limited, Dr. Lal Pathlabs Limited, Metropolis Healthcare Limited, Thyrocare Technologies Limited. (Source: CRISIL Report). We offer a one-stop integrated solution for pathology and radiology testing, and medical consultation services to our customers through our extensive operational network, consisting of our flagship central reference laboratory, 8 satellite laboratories (co-located with our diagnostic centers) and 194 customer touchpoints which include 48 diagnostic centres, and 146 sample collection centres (primarily franchised), as of March 31, 2024 across the states of West Bengal, Bihar, Assam, and Meghalaya. For details of our operational network, see “- Our Operational Network” on page 198. Our flagship central reference laboratory holds the College of American Pathologists accreditation. As of March 31, 2024, we are the only company providing diagnostic services and having a reference laboratory in East and North-East India to hold the College of American Pathologists accreditation. (Source: CRISIL Report). 3 of our laboratories hold National Accreditation Board for Testing and Calibration Laboratories (“NABL”) and 2 of our advanced diagnostic centres hold National Accreditation Board for Hospitals & Healthcare Providers (“NABH”) accreditations. As of March 31, 2024, 43 of our diagnostic centres also housed 120 polyclinic chambers hosting 750+ specialized doctors for patient convenience. During the Fiscal 2024, we conducted approximately 5.98 million tests serving approximately 1.14 million patients and derived 95.48% of our revenue from operations from our core geography, Kolkata and the rest of West Bengal.
|
|
|
Promoter's Holding
|
|
|
|
Total Share Capital
|
31802034
|
|
|
|
Offered to Public
|
13432533
|
|
|
|
Promoter's Holding (Pre-Issue)
|
61.07
|
|
|
|
Promoter's Holding (Post-Issue)
|
48.78
|
|
|
|
|
|
|
|
|
|
|
Address |
Plot No D G-12/1
Action Area 1 D
Premises No 02-0327
New Town
Rajarhat
Kolkata,
West Bengal,
700156
Phone : 033-66059750
Email : investors@surakshanet.com
Website : www.surakshanet.com
|
|
|
Registrar |
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B
Plot 31-32
Gachibowli
Financial District
Nanakramguda
Hyderabad
|
|
|
Listed at |
|
BSE, NSE
|
|
|
Lead Manager |
ICICI Securities Ltd
Nuvama Wealth Management Ltd.
SBI Capital Markets Ltd
|
|
|
Promoters |
Ritu Mittal
Satish Kumar Verma
Somnath Chatterjee
|
|
